Therapeutic Focus Areas

Immunomedics is committed to boldly develop and deliver life-changing cancer therapies

Therapeutic banner

Triple-Negative Breast Cancer (TNBC)

Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer, accounting for up to 20 percent of all breast cancers. TNBC is diagnosed more frequently in younger and premenopausal women and is highly prevalent in African American and Hispanic women.

TNBC cells do not have estrogen or progesterone hormone receptors, or very much of the human epidermal growth factor receptor 2 – hence the term triple negative. This means that medicines that target these receptors are not typically effective in TNBC.

Developing reliable and effective treatments for people living with TNBC is one of the great challenges in breast cancer research today. Immunomedics’ first approved ADC therapy is now a treatment option for people living with metastatic TNBC who have received two or more prior therapies for metastatic disease.

Urothelial Cancer (UC)

Urothelial cancer accounts for about 90 percent of all bladder cancers and can also be found in the renal pelvis, ureter and urethra. Despite the advent of immune checkpoint inhibitor (CPI) therapies, overall response rates to the new treatments remain low. People with urothelial cancer who have relapsed after, or are refractory to, platinum chemotherapy and the recently approved CPI treatments have a significant unmet need with few treatment options available.

Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Breast Cancer (HR+/HER2‒ BC)

HR+/HER2‒ mBC is the most common form of metastatic breast cancer in the U.S. People with HR+/HER2‒ mBC are commonly treated initially with endocrine-based therapies, including CDK 4/6 inhibitors, and then subsequently chemotherapy, but response rates to later line therapies are low. People with visceral metastases have a particularly poor prognosis. New therapeutic options are needed for those individuals with treatment-refractory HR+/HER2‒ mBC, including those with visceral metastases.